Group 1 | Group 1 b | Group 2 | |
---|---|---|---|
N of patients | 32,909 | 7034 | 25,875 |
OAP | 17,056 (51.8%) | 2318 (33.0%) | 14,738 (57.0%) |
Beta-blocker | 24,119 (73.3%) | 4341 (61.7%) | 19,778 (76.4%) |
Statin | 22,123 (67.2%) | 3387 (48.2%) | 18,736 (72.4%) |
ACE inhibitor or ARB | 18,663 (56.7%) | 3167 (45.0%) | 15,496 (59.9%) |
Number of secondary preventive drugs | |||
0 | 4221 (12.8%) | 1644 (23.4%) | 2577 (10.0%) |
1 | 4284 (13.0%) | 1428 (20.3%) | 2856 (11.0%) |
2 | 6497 (19.7%) | 1548 (22.0%) | 4949 (19.1%) |
3 | 9069 (27.6%) | 1434 (20.4%) | 7635 (29.5%) |
4 | 8838 (26.9%) | 980 (13.9%) | 7858 (30.4%) |
mean (+/−sd) | 2.4 (1.3) | 1.8 (1.4) | 2.6 (1.3) |
range (min; max) | 0.0; 4.0 | 0.0; 4.0 | 0.0; 4.0 |
median (Q1; Q3) | 3.0 (1.0; 4.0) | 2.0 (1.0; 3.0) | 3.0 (2.0; 4.0) |